TLSA Tiziana Life Sciences Ltd

$TLSA when the XBI and a lot of other biotechs are getting slaughtered, Tiziana is only just starting its rerate. Hugely undervalued due to an ATM which looks like it has just closed. Now the countdown to the data release in a few weeks time which will derisk the entire platform of indications. Data unblinded next week. We could be saying hello to $3-$5 very soon! $XBI

$TLSA the stock market is a mechanism for transferring wealth from the impatient to the patient (Buffett). TLSA could be a monster in the making. ATHs at just $12, easy to reach on positive catalysts.

$TLSA If you don’t own Tiziana right now, you’re missing the easiest risk/reward setup in biotech. Basically you’re a crazy person 🔥 The Setup: • Artificial Floor: The Jefferies ATM wall is currently pinning down the share price. The second they turn it off ahead of data, the share price will undoubtedly rally hard • Massive Catalyst: Phase 2a non-active SPMS PET scan data dropping in a few weeks. This is a complete platform de-risking event. • Multi-Indication Engine: It’s not just SPMS—intranasal foralumab targets Alzheimer’s, ALS, and MSA. • Big Pharma Waiting: CEO confirmed multiple global majors asked to see the SPMS data first before making their move. Basically you’re going to see a partnership 🎯 Price Targets: • Pre-Data Rally: $2.00 (once ATM turns off & FOMO takes over) • Positive Data: $5.00+ minimum • Partnership/Buyout: Sky-high re-rating once the deal drops. Get in before the wall disappears. 🚀 $XBI $LABU

$TLSA not financial advice but some observations we were trading at $2.50 last July. What changed in a little over one year other than better fundamentals from strong execution, several positive clinical updates, several substantial insider buying, international partnership and getting much closer to our data update ? Oh yeah a little dilution from ATM that is some necessary balance sheet strengthening and it’s nothing in the big picture relative to our TAM. Am I missing something?

$TLSA worth noting that RRMS accounts for the vast majority of all multiple sclerosis patients. Tiziana and KAIMRC intend to evaluate intranasal foralumab in combination with existing anti-CD20 therapies for RRMS patients who are responding poorly to standard treatment. Proving efficacy via the October data will force the market to re-rate Tiziana from a niche na-SPMS developer into a platform company actively addressing the entire global MS market. But also don’t forget the other indications- MSA, traumatic brain injury and Alzheimer’s! Just a huge opportunity here $XBI $LABU

A small but easy-to-miss detail in today’s news: $TLSA updated the Phase 2 topline timing to October, narrowing the previous guidance of late Q3/early Q4.

$TLSA For anyone new: Tiziana Life Sciences (Nasdaq: TLSA) expects topline data in October from INFORM-MS, its randomised, placebo-controlled Phase 2a trial of intranasal foralumab. Foralumab is a nasal anti-CD3 antibody from Howard Weiner's lab at Brigham and Women's Hospital, targeting the microglial inflammation behind progressive multiple sclerosis, which has no approved treatment in its non-active form. In open-label use, all 14 expanded-access patients were reported stable or improved within six months, with PET scans showing reduced microglial activation. The same mechanism is being pursued in MSA, Alzheimer's, ALS and brain injury, largely grant-funded, so one positive controlled readout could reprice the whole platform. Tiziana signed an MOU with Saudi Arabia's King Abdullah International Medical Research Center, and its founder holds about 35% of the shares. At around $117 million, the market is paying little for an eight-indication platform ahead of a binary catalyst.

$TLSA I am an Italian doctor; I have read and studied Tiziana's research extensively and am very confident about it, especially regarding the structure of the Phase 2 trial. I hold about 40,000 shares—fingers crossed!

$TLSA You know, respect to Ivor for travelling during non-peaceful times in the region and closing the deal. Clearly he cares about the company

$TLSA My old notes from 2024 still relevant. Since then the data has matured well and FDA has approved at-home dosing. Teplizumab got Accelerated approval with 76 patient trial. Foralumab trial has 54 patients+14 from expanded access with a much cleaner safety profile.

$TLSA In my opinion, if the study is a success, it’s not entirely impossible that Tiziana will release the data alongside the partnership that has already been signed. Fingers crossed!

$TLSA huge pipeline for tlsa filled with significant unmet need and upcoming ph 2 catalysts for multiple system atrophy, spms, and alzheimers

$TLSA I would be surprised if we closed lower than $1 from here until the readout. Those of us that have been here for years probably notice how similar this SP action is to the previous periods when we miraculously regained listing compliance without the need for a reverse split. About two more weeks until the data will be made available to the companies that have expressed an early interest.

$TLSA Chairman owns half the co. and CEO and Chairman of tlsa have been buying like hotcakes

$TLSA new MUA in place and CEO has bought 1 million shares in the past few months. Data comes out next month. Coincidence??? I think not!

$TLSA For me, fluctuations don't matter much right now: in any case, if the study goes poorly in a month, the stock will drop to zero. If the study goes reasonably well, I think we’ll be around the 3.00–3.50 mark.

$TLSA Sub-$1 is a gift. All eyes on October data. Outcome expected to be positive, but it's Bios so anyone's guess. Comfortable holding and adding on dips. Long road it's been, but it's nice to be on the horizon of data. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

$TLSA is clearly being manipulated in the last week at least. Shorts are playing with fire by shorting a debt free company while insiders are accumulating over 40% ownership and CEO buying $1 million in August at one dollar a share imho

$TLSA thank you for shorting it will only make this rise more intense when you get squeezed

$TLSA Added more here with $AMFN profits. Phase 2 readout in October for SPMS is likely to be an exciting time for us. For me even more so as an SPMS patient. Still holding a lottery ticket over there, but they’re spending money They don’t have to try to promote the stock. That’s a red flag. There’s still a lot of work to be done and no money with which to do it.